Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)
12.52 x 3 15.00 x 2
Post-market by (Cboe BZX)
14.60 +1.45 (+11.03%) 04/22/25 [NASDAQ]
12.52 x 3 15.00 x 2
Post-market 14.70 +0.10 (+0.68%) 16:33 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
13.41
Day High
14.66
Open 13.41
Previous Close 13.15 13.15
Volume 1,865,694 1,865,694
Avg Vol 1,752,215 1,752,215
Stochastic %K 68.70% 68.70%
Weighted Alpha -27.42 -27.42
5-Day Change +1.33 (+10.02%) +1.33 (+10.02%)
52-Week Range 10.57 - 33.33 10.57 - 33.33
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,909,577
  • Shares Outstanding, K 145,215
  • Annual Sales, $ 0 K
  • Annual Income, $ -422,770 K
  • EBIT $ -487 M
  • EBITDA $ -515 M
  • 60-Month Beta 1.58
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.49

Options Overview Details

View History
  • Implied Volatility 106.40% ( -17.59%)
  • Historical Volatility 87.60%
  • IV Percentile 95%
  • IV Rank 70.01%
  • IV High 132.13% on 04/16/25
  • IV Low 46.31% on 01/21/25
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 16
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 1,171
  • Open Int (30-Day) 1,176

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.73
  • Number of Estimates 11
  • High Estimate -0.67
  • Low Estimate -0.82
  • Prior Year -0.68
  • Growth Rate Est. (year over year) -7.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.57 +38.13%
on 04/07/25
Period Open: 14.43
14.90 -2.03%
on 03/25/25
+0.17 (+1.18%)
since 03/21/25
3-Month
10.57 +38.13%
on 04/07/25
Period Open: 23.31
24.34 -40.03%
on 02/05/25
-8.71 (-37.37%)
since 01/22/25
52-Week
10.57 +38.13%
on 04/07/25
Period Open: 15.99
33.33 -56.20%
on 11/11/24
-1.39 (-8.69%)
since 04/22/24

Most Recent Stories

More News
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

DNLI : 14.60 (+11.03%)
Why You Shouldn't Bet Against Denali (DNLI) Stock

One stock that might be an intriguing choice for investors right now is Denali Therapeutics Inc. DNLI. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings...

DNLI : 14.60 (+11.03%)
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

DNLI : 14.60 (+11.03%)
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

DNLI : 14.60 (+11.03%)
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicleâ„¢ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposiumâ„¢

DNLI : 14.60 (+11.03%)
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

DNLI : 14.60 (+11.03%)
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

DNLI : 14.60 (+11.03%)
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

DNLI : 14.60 (+11.03%)
Denali Therapeutics Initiates Phase 2a Clinical Study of LRRK2 Inhibitor BIIB122 for Parkinson’s Disease

Denali Therapeutics initiates a Phase 2a study of BIIB122 for LRRK2-associated Parkinson's disease, evaluating safety and biomarkers.Quiver AI SummaryDenali Therapeutics Inc. has announced the start of...

DNLI : 14.60 (+11.03%)
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease

DNLI : 14.60 (+11.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program...

See More

Key Turning Points

3rd Resistance Point 15.12
2nd Resistance Point 14.39
1st Resistance Point 13.77
Last Price 14.60
1st Support Level 12.42
2nd Support Level 11.69
3rd Support Level 11.07

See More

52-Week High 33.33
Fibonacci 61.8% 24.64
Fibonacci 50% 21.95
Fibonacci 38.2% 19.26
Last Price 14.60
52-Week Low 10.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro